Seeking Alpha

More on Dendreon (DNDN): Q1 EPS beats on an adjusted basis but misses on a net basis due to...

More on Dendreon (DNDN): Q1 EPS beats on an adjusted basis but misses on a net basis due to one-time severance expenses. Net product revenue for the quarter was $82M, boosted by higher sales of Provenge, compared to $27M for the same prior year period. Shares -8.4% AH.
Comments (4)
  • slowtime
    , contributor
    Comments (32) | Send Message
    Excellent report!!! Beat on the top line, and the bottom line if the one-time severance expenses are excluded.
    7 May 2012, 05:20 PM Reply Like
  • mitrado
    , contributor
    Comments (1972) | Send Message
    It looks very good to me as well, slowtime. I'm tempted to buy tomorrow... but it might drop for one more day, no?
    7 May 2012, 07:07 PM Reply Like
  • slowtime
    , contributor
    Comments (32) | Send Message
    DNDN has been bruised by shorts, charlatans and all sorts of con men.This last quarter shows a company GROWING. And growing with a revolutionary product. First in class are leaders. We must be patient. A major will buy DNDN for$30+.
    8 May 2012, 09:16 AM Reply Like
  • XTigerX
    , contributor
    Comments (246) | Send Message
    Hmmm....the growth curve on the revenues is not even close to what was hoped for last year. I'm out (in November and I'm still bruised) so I suppose I should stfu. However, revenues of 82 million per quarter will not sell this stock ever. That doesn't even count as "gradual growth" if you ask me. This company must achieve the 150 million per quarter before they will impress anyone. One more quarter under 100 million and the new CEO will start getting slagged too. Oh well.....
    7 May 2012, 11:26 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector